ライフサイエンスコーパス: infected person

1 ion and contain the maximum viral load in an infected person.

2 h level, often resulting in the death of the infected person.

3 antibody isolated from an HIV-1 chronically infected person.

4 utes to the dissemination of HIV-1 within an infected person.

5 IV-infected persons when compared to non-HIV-infected persons.

6 -exposed persons and infectiousness of HIV-1-infected persons.

7 is not suitable for all treatment-naive HIV-infected persons.

8 ity among human immunodeficiency virus (HIV)-infected persons.

9 yopathy among asymptomatic Trypanosoma cruzi-infected persons.

10 ansmission and a large reservoir of latently infected persons.

11 is recommended as preventive therapy in HIV-infected persons.

12 ndothelial cell inflammation observed in HIV-infected persons.

13 rent outcomes of disease are observed in HIV-infected persons.

14 T) in all human immunodeficiency virus (HIV)-infected persons.

15 settings; and sexual transmission among HIV-infected persons.

16 iated nephropathy (HIVAN) predominate in HIV-infected persons.

17 sional guidance on the use of HCV PIs in HIV-infected persons.

18 iagnosis and initiation of treatment for HIV-infected persons.

19 common in human immunodeficiency virus (HIV)-infected persons.

20 bclinical atherosclerosis progression in HIV-infected persons.

21 ts for new immune-based interventions in HIV-infected persons.

22 ted availability of samples from acutely HIV-infected persons.

23 ical to the present and future health of HIV-infected persons.

24 that may aid CVD risk stratification in HIV-infected persons.

25 for immunotherapeutic interventions in HIV-1-infected persons.

26 g this significant comorbid infection in HIV-infected persons.

27 lignancies are seen in a small percentage of infected persons.

28 dministration were therefore examined in HIV-infected persons.

29 sphorylation in CD4+ T cell subsets from HIV-infected persons.

30 cant cause of morbidity and mortality in HIV-infected persons.

31 ment, and pathogenesis of hepatitis C in HIV-infected persons.

32 oth naive and memory B-cell subsets from HIV-infected persons.

33 ust find ways to rapidly begin treatment for infected persons.

34 (HIV-1) isolates from newly diagnosed HIV-1-infected persons.

35 breaks of MDR-TB have primarily affected HIV-infected persons.

36 diographic findings were categorized for RSV-infected persons.

37 immunodominant and the other subdominant in infected persons.

38 he function of naive CD4(+) T cells from HIV-infected persons.

39 more readily than drug-susceptible TB in HIV-infected persons.

40 ere 29 588 deaths reported among 145 845 HIV-infected persons.

41 nsive primary CVD prevention strategy in HIV-infected persons.

42 ncy in finding, evaluating, and treating HCV-infected persons.

43 nt HAND or improve cognitive function in HIV-infected persons.

44 topes, revealing new immune responses in HIV-infected persons.

45 included 126 studies describing 491 608 HIV-infected persons.

46 al testing would identify additional 526 HCV-infected persons.

47 sponses in a cohort of untreated HIV clade C-infected persons.

48 n may improve cardiovascular outcomes in HIV-infected persons.

49 ly reduced herpes zoster incidence among HIV-infected persons.

50 ncreased gastric cancer risk among H. pylori-infected persons.

51 philis in human immunodeficiency virus (HIV)-infected persons.

52 target to improve the immune function in HIV-infected persons.

53 estry-specific factor influencing NCI in HIV-infected persons.

54 The frontal cortex from 32 HIV-infected persons (12 without evidence HIV-1 encephalitis

55 1,571 HIV-1-infected persons (47% women) from nine countries in four

56 nfection, the next great frontier is to cure infected persons, a formidable challenge.

57 le similar to the serological profile of HCV-infected persons, although the pathogenicity of this vir

58 ed by direct contact with the body fluids of infected person and objects contaminated with virus or i

59 originating from a CTL line derived from an infected person and specific for the immunodominant HLA-

60 ny type of oral HPV infection was 34% in HIV-infected persons and 19% in HIV-uninfected persons.

61 69M, WI61, A64, and L26, were isolated from infected persons and adapted to cell culture to use as s

62 Evidence defining treatment for HIV-infected persons and for pregnant women is limited, but

63 ession of CD80 similarly in B cells from HIV-infected persons and from healthy controls.

64 ported young ages at cancer diagnosis in HIV-infected persons and have suggested that HIV accelerates

65 We used a national sample of HCV-infected persons and HCV-uninfected controls from the El

66 Anemia is a frequent complication among HIV-infected persons and is associated with faster disease p

67 HSV) remains latent in nerve root ganglia of infected persons and is thought to reactivate several ti

68 ge the use of routine HAV vaccination in HCV-infected persons and its incorporation into clinical pra

69 (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to

70 yte (CTL) clones and cell lines derived from infected persons and targeting diverse epitopes differ b

71 d controlled trials of micronutrients in HIV-infected persons and that most trials used high-dose mul

72 th evaluation and management for chronically infected persons and their contacts and extended testing

73 urance of prompt and effective treatment for infected persons and their sexual partners.

74 ling were observed in cells from viremic HIV-infected persons and were especially pronounced in CD45R

75 rates were seen in approximately half of RSV-infected persons, and pneumonic opacities were typically

76 irus epidemic, the risk of GBS in Zika virus-infected persons, and the clinical management of GBS cas

77 Lifetime healthcare costs for an HCV-infected person are significantly higher than for noninf

78 Although most infected persons are asymptomatic, ZIKV has been associa

79 HIV-infected persons are at greater risk of developing tuber

80 HIV-infected persons are at heightened risk for recurrent co

81 Human immunodeficiency virus (HIV)-infected persons are at higher risk for serious complica

82 Although human immunodeficiency virus (HIV)-infected persons are at increased risk for major cardiov

83 er complications and increased survival, HIV-infected persons are increasingly developing common heal

84 e whether they are chronically infected, and infected persons are monitored and treated; a screen, tr

85 Human immunodeficiency virus type 1 (HIV)-infected persons are more susceptible to tuberculosis th

86 gies to reduce HSV-2 transmission from HIV-1-infected persons are needed.

87 une responses to influenza vaccine among HIV-infected persons are needed.

88 nfluenza vaccine-induced Ab responses in HIV-infected persons are poorly understood.

89 ions are needed, including ensuring that HIV-infected persons are receiving appropriate care and trea

90 chronic HBV infection and close contacts of infected persons are screened and vaccinated if needed;

91 Most HCV-infected persons are unaware of their status yet are at

92 of human cytomegalovirus (HCMV) in latently infected persons are unclear.

93 human immunodeficiency virus type 1 (HIV-1)-infected persons are unknown.

94 Responses in BAL were 15-fold lower in HIV-infected persons as compared to uninfected persons (P =

95 virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated

96 surable biomarker to identify populations of infected persons at high risk for gastric cancer.

97 tion and could be useful for identifying HIV-infected persons at increased NHL risk.

98 iciency virus (HIV)-negative contacts of HIV-infected persons at increased risk of exposure to infect

99 te core isolates were present in chronically infected persons at low frequency (6.4%; range, 0%-32%).

100 shows promise as a tool for identifying HIV-infected persons at risk for NCI.

101 atment to project the life expectancy of HIV-infected persons, based on smoking status.

102 ly active human immunodeficiency virus (HIV)-infected persons be tested at least annually for syphili

103 We estimate that 26% of WNV-infected persons become symptomatic, defined by the pres

104 nities for identifying West Nile virus (WNV)-infected persons before symptoms develop and for charact

105 (IRIS) in human immunodeficiency virus (HIV)-infected persons beginning antiretroviral therapy (ART)

106 VDD was highly prevalent in black HIV- infected persons but did not explain the observed racial

107 ing liver disease in hepatitis C virus (HCV)-infected persons, but is a bottleneck to evaluation, fol

108 ng-term suppression of plasma HIV-1 loads in infected persons, but low-level virus persists and rebou

109 rapy (ART) reduces the infectiousness of HIV-infected persons, but only after testing, linkage to car

110 pulation, and examined differences among HIV-infected persons by RNA level.

111 Early diagnosis is imperative so that infected persons can take measures to stay healthy, get

112 %), corresponding to 2.7 million chronically infected persons (CI, 2.2 to 3.2 million persons) in the

113 nt-naive, human immunodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cA

114 rading system will maximize the treatment of infected persons compared with a DNA-based test but will

115 HIV-infected persons compared with HIV-uninfected persons we

116 igh frequencies of MDSCs were present in HIV-infected persons, compared with healthy controls.

117 nce of non-HIV cancer risk factors among HIV-infected persons contributes to cancer risk, substantial

118 ic network tracing that starts with recently infected persons could support public health efforts to

119 HIV-infected persons demonstrated a higher frequency of posi

120 an unusual pathogen, persisting for years in infected persons despite an immune response.

121 rvation of this response in B cells from HIV-infected persons despite diminished TLR9 expression.

122 HIV/CMV co-infected persons despite prolonged viral suppression oft

123 gnitive disorder (HAND) remain common in HIV-infected persons, despite HAART, but whether anemia pred

124 In contrast, most acutely infected persons detected by the HIV Combo assay demonst

125 stric adenocarcinoma, yet only a fraction of infected persons develop cancer.

126 rial infections worldwide, and virtually all infected persons develop coexisting gastritis, a signatu

127 represent only one-fifth of about 80 000 HCV-infected persons dying that year, at least two-thirds of

128 In this national sample of HIV-infected persons, eGFR and albuminuria levels were stron

129 HBCT is effective at getting HIV-infected persons enrolled in HIV care before they become

130 he full item set was administered to 644 HIV-infected persons enrolled in three ongoing research stud

131 stric adenocarcinoma, yet only a minority of infected persons ever develop this malignancy.

132 iple routes including direct contact with an infected person, fecal matter, or vomitus, and contact w

133 smitted by unprotected physical contact with infected persons, few data exist on which specific bodil

134 Participants included 655 HIV-infected persons followed for up to 6 years in cohort st

135 The apparent cure of an HIV-infected person following hematopoietic stem cell transp

136 o encourage screening and identify and refer infected persons for care by declaring that such interve

137 of the criteria may erroneously exclude HSV-infected persons from a necessary diagnostic test or, al

138 nscriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the Uni

139 TS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 i

140 HIV-infected persons >/= 18 years of age who were previously

141 HIV-infected persons had a 10-fold decrease in total TCR rep

142 Forty-six percent of HIV-infected persons had insomnia (PSQI >5), and 30% reporte

143 ins on insulin resistance or diabetes in HIV-infected persons has not been assessed within a randomiz

144 ity among human immunodeficiency virus (HIV)-infected persons, has been associated with concurrent ri

145 Infected persons have a high prevalence of infection sev

146 HIV-infected persons have a high prevalence of insomnia, but

147 PURPOSE HIV-infected persons have an elevated risk of developing non

148 Mortality rates for HIV-infected persons have become much closer to general mort

149 s common; worldwide, an estimated 10% of HIV-infected persons have chronic hepatitis B.

150 human immunodeficiency virus type 1 (HIV-1)-infected persons have diminished responses to hepatitis

151 Human immunodeficiency virus (HIV)-infected persons have higher rates of herpes zoster than

152 HIV-infected persons have less robust antibody responses to

153 l laboratory indicates that about 1 in 4 HCV-infected persons have levels of liver disease put them a

154 Many chronically infected persons have mild liver disease with little or

155 es viral replication capacity in chronically infected persons; however, little is known about TW10 ep

156 (CVD) is now a leading cause of death in HIV-infected persons; however, risk markers for CVD are ill

157 Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhy

158 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) w

159 ng human immunodeficiency virus type 1 (HIV)-infected persons in Africa.

160 rvival of human immunodeficiency virus (HIV)-infected persons in areas where antiretroviral therapy i

161 the first organ transplantation between HIV-infected persons in Canada, we review Canadian law regar

162 ure policy regarding organ donation from HIV-infected persons in Canada.

163 ucted a retrospective cohort study among HIV-infected persons in care at the Comprehensive Care Cente

164 For HIV-infected persons in care during 2000-2010, rates of firs

165 In our study population of HIV-infected persons in care, women had lower baseline hemog

166 on occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United St

167 The study enrolled 2,490 HIV-infected persons in Lima, Peru, and 230 were microscopy

168 human immunodeficiency virus type 1 (HIV-1)-infected persons in low-middle income countries, thanks

169 We estimated that there are 1.5 million CHB-infected persons in Shanghai.

170 e remains a leading cause of death among HIV-infected persons in the United States and elsewhere.

171 ompared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs

172 These findings suggest that HIV-infected persons in whom the percentage of memory B cell

173 ght be applied to a broader community of HIV-infected persons in whom the risks of HSCT currently out

174 Target Population: HIV-infected persons, including future incident cases.

175 imally defined epitopes in 341 untreated HIV-infected persons, including persons who spontaneously co

176 he causes of low bone mineral density in HIV-infected persons, including the impact of specific antir

177 of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding

178 When a recently infected person is identified, family clustering and com

179 HAV vaccination of all HCV-infected persons is costly and likely to expose many ind

180 primary consideration in treating HCV in HIV-infected persons is the potential for drug interactions.

181 pression was diminished for T cells from HIV-infected persons, it was not directly related to IL-7 re

182 In HIV-infected persons, liver fibrosis is associated with disc

183 s directly proportional to the number of HIV-infected persons living in the home for ILI (RR, 1.39; P

184 mon among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, b

185 ion among human immunodeficiency virus (HIV)-infected persons may contribute to atherosclerosis.

186 n of T-cell subpopulations and that most HIV-infected persons may retain a sufficiently diverse TCR r

187 ination since 1991, offset by numbers of HBV-infected persons migrating to the United States from end

188 In persistently infected persons nAb responses were delayed then progres

189 mmune responses in HIV/HCV-coinfected or HCV-infected persons need to consider current IDU.

190 Helicobacter pylori infection; however, most infected persons never develop this malignancy.

191 D deficiency was not more common among HIV- infected persons, nor did it seem associated with HIV- r

192 Latently infected persons, of which there are estimated to be app

193 RDS identified 4,051 HIV-infected persons, of whom 2,325 (57.4%) were unaware of

194 It also identified 5,777 HCV-infected persons, of whom 5,337 (92.4%) were unaware tha

195 smission through unprotected sex with an HIV-infected person on cART for >6 months.

196 and lipohypertrophy are prevalent among HIV-infected persons on ART.

197 d to assess the benefits of treatment of HCV-infected persons on development of HCC.

198 HIV-infected persons on suppressive antiretroviral therapy (

199 g the V1/V2 domains between Envs of the same infected person or between two persons linked by a trans

200 2000, suggesting late diagnosis of some HIV-infected persons or antiretroviral therapy failure.

201 ly in duration and virologic titer within an infected person over time, an observation that is unexpl

202 ing highly variable shedding patterns, in an infected person over time, is poorly understood.

203 vant T helper 1-type responses were found in infected persons, paralleling the studies in animal mode

204 , household contacts and sex partners of HBV-infected persons, persons born in countries with hepatit

205 ersons, household and sexual contacts of HBV-infected persons, persons requiring immunosuppressive th

206 safety of organ transplantation between HIV-infected persons prompted a change in US American law to

207 HIV-infected persons reach higher levels of influenza seropr

208 45 529 HIV-infected persons received care in an NA-ACCORD-participa

209 We followed a national sample of 17 264 HIV-infected persons receiving care in the Veterans Health A

210 Uninsured and underinsured HIV-infected persons receiving RWHAP assistance were more li

211 number of deaths in hepatitis C virus (HCV)-infected persons recorded on US death certificates has b

212 The degree to which ART offered to infected persons reduces infectiousness is of considerab

213 ing to high-risk individuals, and 50%-75% of infected persons remain unaware of their status.

214 optimal methods to predict MI risks for HIV-infected persons remain unclear.

215 tbreak of variant influenza, the majority of infected persons reported exposures, suggesting that swi

216 Only 18% of HIV-infected persons reported using a sleep medication at le

217 atent tuberculosis infection (LTBI) of HIV-1-infected persons represents a challenge in TB epidemic c

218 Management of these conditions in HIV-infected persons requires careful consideration, balanci

219 not accommodate the increased number of HIV-infected persons requiring care.

220 an increase in T cells in the airways in HIV-infected persons resulted in the overall number of M. tu

221 t of acute HCV genotype-1 infection in HIV-1-infected persons results in a high relapse rate.

222 This article documents cancer risk among HIV-infected persons, reviews immune system effects of HIV i

223 HIV-infected persons should be managed and monitored for all

224 In addition, monocytes from HIV-1-infected persons showed diminished responses to IFNalpha

225 ologic checkpoint inhibitor in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions a

226 Longitudinal analysis of chronically infected persons starting ART revealed that the frequenc

227 ation with lower CD4 and higher VL among HIV-infected persons, suggesting that immune dysfunction mig

228 Among HCV-infected persons, SVR was associated with reduced risk f

229 FT-GIT, 52% [95% CI, 41%-62%]) and among HIV-infected persons (T-SPOT, 52% [95% CI, 40%-63%]; QFT-GIT

230 on-AIDS-defining cancer was higher among HIV-infected persons than among the general population from

231 ate cancer was significantly lower among HIV-infected persons than the general population (SRR, 0.6 [

232 mely studies that estimate the proportion of infected persons that seek care are needed to improve th

233 Interestingly, in one dual-infected person, the neutralizing response to HSV-2 was

234 sed CD83 and CD86 expression on MDC from HCV-infected persons, the ability of MDC to activate naive C

235 -risk equation, and 1 model developed in HIV-infected persons: the Data Collection on Adverse Effects

236 Identification of hepatitis C virus (HCV)-infected persons through screening could lead to interve

237 iciently identifying a maximum number of HIV-infected persons through voluntary HIV testing and initi

238 ty in a cross-sectional comparison of 19 HIV-infected persons to 18 HIV-uninfected controls.

239 A patient navigator linked 97% of infected persons to care.

240 unity in strategic milieus, predisposing HIV-infected persons to complications of acute or chronic in

241 immunodeficiency virus (HIV) evolves within infected persons to escape being destroyed by the host i

242 f persons with chronic HBV infection enables infected persons to receive necessary care to prevent or

243 e examined the ability of T cells from early infected persons to recognize a broad spectrum of potent

244 recommend ART as soon as possible in all HIV infected persons to reduce the risk of disease progressi

245 increasing prevalence of osteoporosis in HIV-infected persons translates into a higher risk of fractu

246 ith anemia and its effect on survival in HIV-infected persons treated with modern combined antiretrov

247 ion during 1 unprotected sex act with an HIV-infected person under combination antiretroviral therapy

248 HIV-infected persons undergoing organ transplantation genera

249 s progression, and HCC development among HCV-infected persons using the Electronically Retrieved Coho

250 protease inhibitors (PIs) prescribed to HIV-infected persons variably modulate cathepsin activities

251 In 2009 a 28-year-old HIV-infected person was estimated to have 45.4 years of life

252 mortality risk in HAV superinfection of HCV-infected persons was 7.23 (95% confidence interval: 1.24

253 lthy donors and human immunodeficiency virus-infected persons was determined by use of ELISPOT.

254 including studies reporting mortality in HCV-infected persons was performed.

255 persons, and among treated and untreated HCV-infected persons.We identified 34,480 matched pairs of H

256 nef quasispecies from nine chronically HIV-1-infected persons were examined for sequence evolution an

257 Infected persons were more likely to be aged 40 to 59 ye

258 antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected perso

259 antiretroviral-treated, immune-restored, HIV-infected persons when compared with HIV-uninfected perso

260 HIV-infected persons who achieve undetectable viral loads on

261 se the proportion of hepatitis C virus (HCV)-infected persons who know their status and are linked to

262 Human immunodeficiency virus type 1 (HIV-1)-infected persons who maintain plasma viral loads of <50

263 HIV-infected persons who were aged 45-65 years, had a plasma

264 e (both MSM and PWID), the prevalence of HIV-infected persons who were unaware of their status increa

265 A hepatitis C virus (HCV)-infected person will ideally have access to quality heal

266 patient is the first reported case of an HIV-infected person with dual Balamuthia mandrillaris and Ac

267 cause of higher susceptibility, because HIV-infected persons with a high peripheral CD4(+) T-cell co

268 Routine vaccination of HIV-infected persons with a quadrivalent meningococcal conju

269 imated proportion of hepatitis C virus (HCV)-infected persons with advanced fibrosis or cirrhosis is

270 fic CD4(+) T cell responses in untreated HIV-infected persons with and without neutralizing antibodie

271 ion among human immunodeficiency virus (HIV)-infected persons with antiretroviral therapy (ART)-assoc

272 cells were relatively well maintained in HIV-infected persons with aTB, despite severe immunodeficien

273 lic and health care providers and linkage of infected persons with care and treatment services can in

274 cal guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 x 10(9

275 ce on the effectiveness of treatments in HIV-infected persons with CD4 counts greater than 0.200 x 10

276 inant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and

277 Treatment of African HSV-2/HIV-1-infected persons with daily suppressive acyclovir did no

278 the use of a single dose of BPG to treat HIV-infected persons with early syphilis.

279 fail to identify substantial numbers of HIV-infected persons with elevated CVD risk who could potent

280 HIV-infected persons with high VACS Index scores are at incr

281 s not associated with insomnia; however, HIV-infected persons with insomnia were 3.1-fold more likely

282 n interpreting absolute CD4(+) counts of HIV-infected persons with known or suspected liver disease,

283 Projected 5-y survival in HIV-infected persons with LAB-CD4 is 60.9% (95% CI, 60.9%-61

284 portional hazard ratios for mortality in HIV-infected persons with lung disease during the HAART era.

285 HIV-infected persons with multiple anal HPV types or a nadir

286 Our results indicate that HIV-infected persons with neutralizing antibodies have signi

287 ciency may attenuate disease among H. pylori-infected persons with no response to antibiotics.

288 The long-term survival of HIV-infected persons with symptomatic cryptococcal meningiti

289 y when treating human immunodeficiency virus-infected persons with syphilis.

290 ontrollers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in

291 rsons per day, and the detection rate of HIV-infected persons with viremia (regardless of their aware

292 We show that HIV/CMV co-infected persons with virologic suppression and recovere

293 idence of non-AIDS-defining events among HIV-infected persons with virological suppression should con

294 AD was positive for 5.1% of asymptomatic HIV-infected persons, with higher rates among those with nas

295 low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection.

296 autophagy was observed in the brains of HIV-infected persons without HIV-1 encephalitis compared wit

297 s of autophagy compared with brains from HIV-infected persons without HIV-1 encephalitis or HIV-uninf

298 aria transmission, in Africa many falciparum-infected persons without smear-detectable gametocytes st

299 achieve 73% virologic suppression among HIV-infected persons worldwide by 2020.

300 o meet the critical goal of treating all HIV-infected persons worldwide, there is movement toward ext